Despite some excellent clinical results, PD-1/PD-L1 antibody agents still face challenges such as low response rates, low binding intensity and uncontrollable side effects, while small molecule inhibitors also face unsuitable rapid clearance rates and low tumor site accumulation (37). Here, PDCD1 is linked to neoplasm.